109 related articles for article (PubMed ID: 15373969)
1. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells.
Marshak-Rothstein A; Busconi L; Lau CM; Tabor AS; Leadbetter EA; Akira S; Krieg AM; Lipford GB; Viglianti GA; Rifkin IR
J Endotoxin Res; 2004; 10(4):247-51. PubMed ID: 15373969
[TBL] [Abstract][Full Text] [Related]
2. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides.
Wang Y; Krieg AM
Vaccine; 2004 Jun; 22(20):2641-50. PubMed ID: 15193390
[TBL] [Abstract][Full Text] [Related]
3. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
4. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
5. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
Brummel R; Roberts TL; Stacey KJ; Lenert P
Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
[TBL] [Abstract][Full Text] [Related]
6. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways.
Yasuda K; Ogawa Y; Yamane I; Nishikawa M; Takakura Y
J Leukoc Biol; 2005 Jan; 77(1):71-9. PubMed ID: 15496451
[TBL] [Abstract][Full Text] [Related]
7. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA.
Yasuda K; Rutz M; Schlatter B; Metzger J; Luppa PB; Schmitz F; Haas T; Heit A; Bauer S; Wagner H
Eur J Immunol; 2006 Feb; 36(2):431-6. PubMed ID: 16421948
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.
Rutz M; Metzger J; Gellert T; Luppa P; Lipford GB; Wagner H; Bauer S
Eur J Immunol; 2004 Sep; 34(9):2541-50. PubMed ID: 15307186
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
11. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
12. TLR9 in health and disease.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):155-81. PubMed ID: 16818370
[TBL] [Abstract][Full Text] [Related]
13. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
14. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
15. TLR9 and the recognition of self and non-self nucleic acids.
Lamphier MS; Sirois CM; Verma A; Golenbock DT; Latz E
Ann N Y Acad Sci; 2006 Oct; 1082():31-43. PubMed ID: 17145922
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of T(H)-1 type response by immunoactive AT oligonucleotide from lactic acid bacteria via Toll-like receptor 9 signaling.
Shimosato T; Kitazawa H; Katoh S; Tohno M; Iliev ID; Nagasawa C; Kimura T; Kawai Y; Saito T
Biochem Biophys Res Commun; 2005 Jan; 326(4):782-7. PubMed ID: 15607737
[TBL] [Abstract][Full Text] [Related]
18. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
Fehér K
Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
[TBL] [Abstract][Full Text] [Related]
19. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells.
Hu D; Su X; Sun R; Yang G; Wang H; Ren J; Sun L; Wu X; Hu X; Yu Y; Wang L
Mol Immunol; 2009 Apr; 46(7):1387-96. PubMed ID: 19201477
[TBL] [Abstract][Full Text] [Related]
20. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.
Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA
Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
